OncoMatch/Clinical Trials/NCT06249282
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Is NCT06249282 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Carfilzomib and Sotorasib for advanced lung non-small cell carcinoma.
Treatment: Carfilzomib · Sotorasib — This phase I trial tests the safety, side effects, and best dose of carfilzomib in combination with sotorasib in treating patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Carfilzomib is a drug that binds to and inhibits the activity of the protein complex that is responsible for degrading other damaged or unneeded proteins. The inhibition of this protein by carfilzomib can then cause tumor growth inhibition and cell death. Sotorasib is a drug that binds to and inhibits the activity of the KRAS G12C mutant. This may inhibit growth in KRAS G12C-expressing tumor cells. Combining carfilzomib and sotorasib may be a safe and effective treatment option for patients with KRAS G12C-mutated advanced or metastatic NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS g12c
Disease stage
Required: Stage III, IV (AJCC v8)
Metastatic disease required
Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Histologically confirmed NSCLC that is metastatic or advanced
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: KRAS inhibitor
Failed prior KRAS inhibitor
Cannot have received: chemotherapy
Chemotherapy or immunotherapy within 21 days prior to day 1 of protocol therapy
Cannot have received: immunotherapy
Chemotherapy or immunotherapy within 21 days prior to day 1 of protocol therapy
Cannot have received: radiation therapy
Radiation therapy within 14 days prior to day 1 of protocol therapy
Cannot have received: KRAS inhibitor
KRAS inhibitor within 14 days prior to day 1 of protocol therapy
Cannot have received: investigational therapy
Investigational therapy within 28 days prior to day 1 of protocol therapy (or 5 half-lives, use whichever is shorter)
Lab requirements
Blood counts
ANC ≥ 1,500/mm^3; Hemoglobin (Hb) ≥ 9 g/dL; Platelets ≥ 100,000/mm^3
Kidney function
Creatinine clearance of ≤ 1.5 x ULN or GFR ≥ 60 mL/min/1.73 m^2
Liver function
Total bilirubin ≤ 1.5 x ULN (unless has Gilbert's disease); AST ≤ 3 x ULN (or ≤ 5 x ULN in the setting of liver metastatic disease); ALT ≤ 5 x ULN (or ≤ 5 x ULN in the setting of liver metastatic disease)
Cardiac function
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
ANC ≥ 1,500/mm^3; Hemoglobin (Hb) ≥ 9 g/dL; Platelets ≥ 100,000/mm^3; Total bilirubin ≤ 1.5 x ULN (unless has Gilbert's disease); AST ≤ 3 x ULN (or ≤ 5 x ULN in the setting of liver metastatic disease); ALT ≤ 5 x ULN (or ≤ 5 x ULN in the setting of liver metastatic disease); Creatinine clearance of ≤ 1.5 x ULN or GFR ≥ 60 mL/min/1.73 m^2; NYHA class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
- City of Hope at Irvine Lennar · Irvine, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify